Researchers from Pritzker Molecular Engineering, under the guidance of Prof. Jeffrey Hubbell, demonstrated that their compound can eliminate the autoimmune response linked to multiple sclerosis. Researchers at the University of Chicago's Pritzker School of Molecular Engineering (PME) have developed
Seems that trials are already happening. As a person living with UC, this could be a game changer.
It’s be a bit premature to do that, if you’re interested as a patient or layperson. It will also be all over the news in five years or so if it works and they bring it to market.
However, it looks like you could make an alert for the company name (Anokion SA) if you’re interested.
Those trials are conducted by the pharmaceutical company Anokion SA, which helped fund the new work and which Hubbell cofounded and is a consultant, board member, and equity holder
It’s be a bit premature to do that, if you’re interested as a patient or layperson. It will also be all over the news in five years or so if it works and they bring it to market.
However, it looks like you could make an alert for the company name (Anokion SA) if you’re interested.